Theravance SVP reports tax share withholding

Theravance Biopharma SVP Brett A. Grimaud reported a tax-related share disposition.

Rhea-AI Filing Summary

Theravance Biopharma SVP Brett A. Grimaud reported a tax-related share disposition. On this Form 4, 20,833 Ordinary Shares were withheld at $19.66 per share to cover tax obligations from vesting restricted stock units. This was a transaction with the company, not an open-market trade, and left him holding 334,449 shares directly.

Insider Trade Summary

Exercise Price or Tax Liability: 20,833 shares

Exercise Price or Tax Liability 1 txn

Insider Grimaud Brett A.

Role SVP, GEN COUNSEL AND SECRETARY

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	20,833	$19.66	$410K

Holdings After Transaction: Ordinary Shares — 334,449 shares (Direct)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Theravance Biopharma (TBPH) insider Brett A. Grimaud report on this Form 4?

Brett A. Grimaud reported a tax-withholding disposition of 20,833 Ordinary Shares. The shares were withheld by Theravance Biopharma to satisfy tax obligations from vesting restricted stock units, rather than sold in the open market.

How many Theravance Biopharma (TBPH) shares were disposed of for taxes and at what price?

The filing shows 20,833 Ordinary Shares were withheld at $19.66 per share. This tax-withholding disposition covered obligations arising from vesting restricted stock units and was conducted directly with the issuer, not through open-market trading.

Did Theravance Biopharma (TBPH) SVP Brett A. Grimaud sell shares in the open market?

No, the Form 4 states the share disposition was with the issuer to satisfy tax obligations. The footnote clarifies that this tax withholding did not involve any open-market transaction or discretionary share sale.

How many Theravance Biopharma (TBPH) shares does Brett A. Grimaud hold after this transaction?

After the tax-withholding disposition, Brett A. Grimaud directly holds 334,449 Ordinary Shares. This total reflects his position following the 20,833 shares withheld to cover taxes on vesting restricted stock units, as reported in the Form 4.

What does transaction code F mean in the Theravance Biopharma (TBPH) Form 4?

Transaction code F indicates shares were used to pay an exercise price or tax liability. Here, 20,833 shares were withheld to cover tax obligations from vesting restricted stock units, rather than being sold as a typical open-market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 07:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grimaud Brett A.

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GEN COUNSEL AND SECRETARY

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/20/2026		F		20,833(1)	D	$19.66	334,449	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.